COVID-19 vaccination in cancer patients: Immune responses one year after the third dose
Authors:
- Roberta CampagnaRCRoberta Campagna
- Federica DominelliFDFederica Dominelli
- Maria Antonella ZingaropoliMaria Antonella Zingaropoli
- Fabio CiurluiniFCFabio Ciurluini
- Giorgia GrilliGGGiorgia Grilli
- Alessandra AmorosoAAAlessandra Amoroso
- Angelo De DomenicoADAngelo De Domenico
- Donatella AmatoreDADonatella Amatore
- Maria Stella LiaMLMaria Stella Lia
- Enrico CortesiECEnrico Cortesi
- Vincenzo PiconeVPVincenzo Picone
- Claudio Maria MastroianniCMClaudio Maria Mastroianni
Open Access
- 17 March 2024
- Vol. 42 (10) , 2687-2694
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Clinical characteristics and outcomes of healthcare workers with COVID-19 pre- and postvaccinationJournal of Medical Virology, 2022
- Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home ResidentsDrugs & Aging, 2022
- SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer AgentsJAMA Oncology, 2022
- COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancerCancer Cell, 2021
- Chemotherapy: a double-edged sword in cancer treatmentCancer Immunology, Immunotherapy, 2021
- SARS-CoV-2 VaccinesJAMA, 2021
- Adaptive immunity to SARS-CoV-2 and COVID-19Cell, 2021
- Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studiesCancer, 2020
- Oncology Practice During the COVID-19 PandemicJAMA, 2020
- Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, ChinaAnnals of Oncology, 2020